Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. (“Pearsanta”), has entered into a Market Development Collaboration Agreement (the “Agreement”) with women’s health pioneer Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM) focused on Pearsanta’s blood-based diagnostic test for endometriosis.

Endometriosis is a chronic disease associated with severe, life-impacting pain. It affects approximately one in ten women of reproductive age around the world – approximately 190 million women and girls - according to the World Health Organization.¹

Pearsanta’s Mitomic Endometriosis Test (“MET”) looks for a specific deletion in mitochondrial DNA (“mtDNA”), which is a novel, proprietary biomarker for endometriosis. There are currently no validated blood-based tests for endometriosis available in the United States or anywhere around the world.

Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date, over 300 endometriosis cases have been evaluated using the MET; 600 are planned to support its clinical validation.

This collaboration supports Evofem’s strategy to expand its commercial offering of innovative products that address key challenges in women’s health. The company currently commercializes a single-dose oral treatment for bacterial vaginosis and trichomoniasis and a hormone-free contraceptive vaginal gel. Its long-term goal is to deliver comprehensive healthcare solutions spanning prevention, diagnosis and treatment of sexual and reproductive health concerns facing women at every stage of life.

“We believe that Evofem's proven expertise and strategic focus on women’s health make them the ideal partner for the U.S. launch of our Mitomic Endometriosis Test. Their deep industry knowledge and established relationships will be invaluable as we introduce this innovative diagnostic to the market and pave the way for future applications of our mitochondrial DNA platform,” said Christopher Mitton, President of Pearsanta.

Endometriosis has a profound impact on women's health, with significant implications beyond painful symptoms. Studies indicate that approximately 70% of women with endometriosis experience chronic pelvic pain, which can be debilitating and affect daily functioning. Moreover, nearly 50% of women with endometriosis also face challenges with infertility, as the condition is a leading cause of female infertility. Additionally, endometriosis is associated with a higher risk of comorbid conditions such as irritable bowel syndrome (IBS) and interstitial cystitis, complicating overall health management. The condition can lead to substantial psychological stress, with many women reporting anxiety, depression, and a reduced quality of life due to persistent pain and infertility issues.